A 55-year-old man presents with a small-bowel perforation, and sepsis develops. Treatment with recombinant human activated protein C is recommended. Activated protein C inhibits the procoagulant state in sepsis and may also inhibit the systemic inflammatory response. The clinical benefit and recommendations for use of recombinant human activated protein C are controversial. The risk of bleeding is increased with use of the drug.
No takes yet. Share an insight, caveat, or question.
Toussaint et al. (2009) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: